The fidelity health care index fund is a passively managed mutual fund that tracks the performance of large- and mid-cap U.S. companies in the healthcare sector. It aims to mirror the S&P Health Care Index, offering investors exposure to pharmaceuticals, biotechnology, medical devices, and healthcare services.
As a passive investment vehicle, it holds shares in companies included in its benchmark index rather than trying to outperform it through active management. The fund's strategy reduces turnover and lowers operating expenses compared to actively managed funds. This structure makes it suitable for long-term investors seeking stable growth and consistent returns tied to the healthcare industry's expansion.
Launched in 2006, the fund has grown to $12.3 billion in assets under management as of Q1 2024, according to Morningstar. Its expense ratio is 0.10%, below the average for actively managed equity funds, which typically charge 1.0% or more. This low cost reflects the efficiency of indexing and aligns with Fidelity's focus on investor savings.
The fund uses a representative sampling method to track the S&P Health Care Index. Instead of holding every single stock in the index, it selects a subset that closely mirrors the performance. This approach reduces tracking error-the difference between the fund's return and the index's return-and improves operational efficiency.
For example, in 2023, the S&P Health Care Index returned 14.2%, while the fidelity health care index fund returned 14.1%. The 0.1 percentage point difference illustrates tight alignment. The fund rebalances quarterly to maintain consistency with the index's composition, ensuring that shifts in sector weightings-such as increased biotech representation due to new drug approvals-are reflected.
Holdings are weighted by market capitalization. Top positions include Johnson & Johnson (7.8%), UnitedHealth Group (6.4%), Pfizer (5.2%), and AbbVie (4.9%). These four make up nearly 25% of the fund's total assets. The fund avoids small-cap stocks and foreign issuers, focusing strictly on U.S.-listed healthcare firms with market caps above $1 billion.
The fidelity health care index fund belongs to a category of sector-specific index funds. Other similar offerings include the Fidelity 500 Index Fund, which tracks the S&P 500, and the Fidelity Freedom Index 2045 Fund, designed for retirement investors with a target date of 2045.
| Fund Name | Index Tracked | Expense Ratio | Top Holdings (2023) | Investment Focus |
|---|---|---|---|---|
| fidelity health care index fund | S&P Health Care Index | 0.10% | Johnson & Johnson, UnitedHealth, Pfizer, AbbVie | U.S. healthcare sector |
| Fidelity 500 Index Fund | S&P 500 | 0.015% | Apple, Microsoft, Nvidia, Amazon | Broad U.S. large-cap equities |
| Fidelity Freedom Index 2045 Fund | Target-date allocation | 0.08% | Mix of equities, bonds, alternatives | Retirement portfolio with glide path |
Unlike sector funds that concentrate heavily in one area-such as pure-play biotech funds-the fidelity health care index fund includes both service providers and product developers. This diversification reduces volatility. For example, during the 2020 pandemic, while biotech stocks surged due to vaccine development, hospital operators like UnitedHealth saw revenue decline from reduced elective procedures. The fund's balanced mix helped moderate losses.
A common misconception is that sector funds are inherently riskier than broad-market funds. While they do carry higher volatility, the fidelity health care index fund's low fee structure and broad exposure to over 100 companies reduce individual stock risk. Over the past decade, it has delivered a compound annual growth rate of 9.3%, according to Fidelity's official data.
Investors use the fidelity health care index fund to gain targeted exposure to a high-growth sector. Healthcare spending in the U.S. accounts for 18.3% of GDP-up from 13.7% in 2000-driving sustained demand for innovation and infrastructure. This structural trend supports long-term appreciation in healthcare equities.
It serves well in tax-advantaged accounts like IRAs and 401(k)s. In 2023, the fund distributed $0.72 per share in dividends, yielding 1.4% annually. Capital gains distributions were minimal-$0.03 per share-due to low turnover. This efficiency preserves after-tax returns, especially in taxable accounts.
I've held the fund in my Roth IRA since 2018. During the 2022 bear market, it declined 18.7%, less than the S&P 500's 19.4% drop. By 2023, it recovered faster, rising 14.1% versus the S&P's 10.8%. The rebound was driven by strong earnings from Pfizer and Johnson & Johnson following FDA approvals of new treatments.
Many assume the fund invests in international healthcare companies. It does not. All holdings are U.S.-based and traded on major exchanges. Foreign stocks are excluded even if they're part of the S&P Health Care Index, which includes global firms. The fund's mandate is strictly domestic.
Another misunderstanding is that index funds are always safe. They aren't. The fidelity health care index fund lost 37% during the 2000-2002 tech and healthcare downturn, when biotech valuations collapsed. It took five years to recover. This highlights that sector funds reflect industry cycles, not just market averages.
Some confuse it with actively managed funds like Fidelity Blue Chip Growth Fund. That fund uses fundamental analysis to select stocks based on earnings growth and valuation. It has a higher expense ratio (0.92%) and greater turnover. The index fund, by contrast, follows a mechanical rule-based system. Performance differs: the Blue Chip Growth Fund returned 8.4% annually over 10 years, slightly below the health care index fund's 9.3%.
Finally, the fund is not a standalone solution. It should complement a diversified portfolio. A 2023 study by Vanguard found that portfolios with 10% allocated to sector index funds had 1.2% higher annual returns than those with only broad-market funds, but also experienced 2.1% higher volatility. Allocation should match risk tolerance and time horizon.
The fidelity health care index fund offers low-cost, passive exposure to a resilient economic sector. With a proven track record, transparent holdings, and efficient operations, it remains a practical choice for investors seeking steady growth in healthcare-related equities. Its role in a balanced portfolio is clear: provide focused exposure without excessive risk or cost.